KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO.

Henry J Kaminski, Carlo Antozzi, Ali A Habib, Robert M Pascuzzi, Sabrina Sacconi, Kimiaki Utsugisawa, John Vissing, Antoine Regnault, Asha Hareendran, Fiona Grimson, Thaïs Tarancón, Vera Bril, MycarinG study investigators

Eur J Neurol 32(8) e70231

PMID40755069
PMCIDPMC12319238
DOI10.1111/ene.70231
发表日期2025-08-04
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。
摘要

摘要

BACKGROUND: In the Phase 3 MycarinG study (NCT03971422), rozanolixizumab improved myasthenia gravis (MG)-specific outcomes versus placebo in patients with generalised MG, including those measured by the five independent MG Symptoms patient-reported outcome (PRO) scales: Muscle Weakness Fatigability (MWF), Physical Fatigue (PF) and Bulbar Muscle Weakness (BMW) as secondary endpoints and Ocular Muscle Weakness and Respiratory Muscle Weakness (exploratory endpoints). This research aimed to provide further insights into these improvements. METHODS: Post hoc analyses evaluated correlation (Pearson coefficient) between MG Symptoms PRO and subdomain scores of MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) at baseline. Proportions of responders reaching clinically meaningful thresholds and analyses at the item level (observed mean change and Rasch modelling of predicted change from baseline) are reported for MWF, PF, and BMW with rozanolixizumab versus placebo at Day 43. RESULTS: Correlation coefficients between MG Symptoms PRO and MG-ADL were strong (≥ 0.7) for ocular and bulbar scores and moderate (0.5 to < 0.7) for other scores. Correlations with clinician-assessed QMG scores were generally weak (< 0.5). For MWF, PF, and BMW, greater proportions of responders were observed with rozanolixizumab 7 mg/kg (46.9%, 31.3% and 26.6%, respectively) or 10 mg/kg (56.5%, 48.4% and 32.3%) versus placebo (28.1%, 26.6% and 10.9%). Item-level analyses demonstrated rozanolixizumab benefit at a symptom-specific level. DISCUSSION: MG Symptoms PRO scales correlate well with concepts in MG-ADL while assessing additional concepts, such as PF and MWF. Results from the MG Symptoms PRO in MycarinG reflected improvements from baseline in patient-relevant symptoms, including fatigue, with rozanolixizumab.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Correlations between MG Symptoms PRO scales and subdomains of (a) MG‐ADL and (b) QMG. MG Symptoms PRO data at baseline were recorded for all treated patients. MG, myasthenia gravis; MG‐ADL, Myasthenia Gravis Activities of Daily Living; PRO, patient‐reported outcome; QMG, Quantitative Myasthenia Gravis.
非 KM Figure
FIGURE 2FIGURE 2 Proportions of patients achieving a meaningful improvement at Day 43 in (a) Muscle Weakness Fatigability, (b) Physical Fatigue and (c) Bulbar Muscle Weakness. RLZ, rozanolixizumab.
非 KM Figure
FIGURE 3FIGURE 3 Mean change from baseline at Day 43 in item scores for (a) Muscle Weakness Fatigability, (b) Physical Fatigue and (c) Bulbar Muscle Weakness. Mean change from baseline in raw scores for each item. RLZ, rozanolixizumab.
非 KM Figure
FIGURE 4FIGURE 4 Most probable response to MG Symptoms PRO items pre‐treatment (Day 1) and post‐treatment (Day 43) based on the Rasch model probability framework by treatment group for (a) Muscle Weakness Fatigability, (b) Physical Fatigue and (c) Bulbar Muscle Weakness. The items are ordered according to their severity (as per the estimation from the initial Rasch model). The dotted lines represent the observed means of overall symptom severity observed in the study for the treatment group at the visit. The coloured bars show the most likely response to the item. RLZ, rozanolixizumab.
非 KM Figure